Arch Biopartners Inc. (ARCH.V) TSXV

1.18

-0.01(-0.84%)

Updated at October 03 03:59PM

Currency In CAD

Arch Biopartners Inc.

Address

27 Street Clair Avenue East

Toronto, ON M4T 2M5

Canada

Phone

647-428-7031

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

First IPO Date

May 07, 2010

Key Executives

NameTitlePayYear Born
Mr. Richard Gabriel MuruveCo-Founder, Chief Executive Officer, President & Director150,0001971
Mr. Aaron BensonDirector of Communications & Clinical Data Management0N/A
Mr. Andrew Bishop CFAChief Financial Officer & Director01966
Dr. Daniel Abraham Muruve M.D.Co-Founder, Chief Science Officer & Member of Scientific Advisory Board0N/A
Dr. Justin MacDonald Ph.D.Co-Founder & Principal Scientist0N/A
Dr. Paul BeckCo-Founder & Principal Scientist0N/A

Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.